<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DD89320-C290-488B-BAE0-9023CF9F72D4"><gtr:id>9DD89320-C290-488B-BAE0-9023CF9F72D4</gtr:id><gtr:name>Septodont Limited</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF0FF56D-9D05-41C7-BA7C-D355D5A74843"><gtr:id>FF0FF56D-9D05-41C7-BA7C-D355D5A74843</gtr:id><gtr:name>BioEden Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D94DB040-82E5-4290-AB93-5A50688D472C"><gtr:id>D94DB040-82E5-4290-AB93-5A50688D472C</gtr:id><gtr:name>Mission Therapeutics</gtr:name><gtr:address><gtr:line1>Moneta
Babraham Research Campus</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD"><gtr:id>CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD</gtr:id><gtr:name>Locate Therapeutics Limited</gtr:name><gtr:address><gtr:line1>MediCity</gtr:line1><gtr:line2>Thane Road</gtr:line2><gtr:line3>Beeston</gtr:line3><gtr:postCode>NG90 6BH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D14589F4-C353-4E2D-A95F-4A79BB80786B"><gtr:id>D14589F4-C353-4E2D-A95F-4A79BB80786B</gtr:id><gtr:name>TEVA Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DD89320-C290-488B-BAE0-9023CF9F72D4"><gtr:id>9DD89320-C290-488B-BAE0-9023CF9F72D4</gtr:id><gtr:name>Septodont Limited</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF0FF56D-9D05-41C7-BA7C-D355D5A74843"><gtr:id>FF0FF56D-9D05-41C7-BA7C-D355D5A74843</gtr:id><gtr:name>BioEden Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D94DB040-82E5-4290-AB93-5A50688D472C"><gtr:id>D94DB040-82E5-4290-AB93-5A50688D472C</gtr:id><gtr:name>Mission Therapeutics</gtr:name><gtr:address><gtr:line1>Moneta
Babraham Research Campus</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD"><gtr:id>CAD9680E-741A-4EEE-A6A5-8DEFCA4D03AD</gtr:id><gtr:name>Locate Therapeutics Limited</gtr:name><gtr:address><gtr:line1>MediCity</gtr:line1><gtr:line2>Thane Road</gtr:line2><gtr:line3>Beeston</gtr:line3><gtr:postCode>NG90 6BH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D14589F4-C353-4E2D-A95F-4A79BB80786B"><gtr:id>D14589F4-C353-4E2D-A95F-4A79BB80786B</gtr:id><gtr:name>TEVA Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB338F3D-5DD7-4F82-8CB9-B2B0A481647D"><gtr:id>FB338F3D-5DD7-4F82-8CB9-B2B0A481647D</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Gregory</gtr:otherNames><gtr:surname>Bligh</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14108"><gtr:id>9EB2F540-AB95-4B9C-B6EA-97FC83E3839A</gtr:id><gtr:title>Accelerating translational research through Cardiff University?s Clinical Innovation pipeline</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14108</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Locate Therapeutics Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Locate Therapeutics</gtr:description><gtr:id>1D0C562B-752E-4616-BD56-9272ED50E688</gtr:id><gtr:impact>preparation of proposal for industry funding</gtr:impact><gtr:outcomeId>58c1658c473bf3.67124244-1</gtr:outcomeId><gtr:partnerContribution>preparation of proposal for industry funding</gtr:partnerContribution><gtr:piContribution>preparation of proposal for industry funding</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Septodont Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Septodont</gtr:description><gtr:id>4AE932CD-63B4-4661-AC34-E1506B8C8AD0</gtr:id><gtr:impact>preparation of proposal for industry funding</gtr:impact><gtr:outcomeId>58c1652e287934.09461218-1</gtr:outcomeId><gtr:partnerContribution>preparation of proposal for industry funding</gtr:partnerContribution><gtr:piContribution>preparation of proposal for industry funding</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BioEden Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Bioeden</gtr:description><gtr:id>DFA4EAA9-27E1-4E63-9A32-41D8F034E793</gtr:id><gtr:impact>Submission in September 2016 of a grant to the European Research Council (?1.5M).</gtr:impact><gtr:outcomeId>58c166126bda66.71936896-1</gtr:outcomeId><gtr:partnerContribution>This project has cemented a collaborative partnership with Dr Mike Byrom of BioEden, providing cells in addition to translational direction.
Dental pulp stem cells (received from our industrial collaborator, BioEden)</gtr:partnerContribution><gtr:piContribution>The project provided preliminary results for the submission in September 2016 of a grant to the European Research Council (?1.5M). The research proposal matches funding criteria for providing highly novel interdisciplinarly research, supported by strongly established collaborative research network to aid successful development of new avenues for the therapeutic application of dental pulp derived mesenchymal stem cells in tissue engineering.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MISSION Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mission</gtr:description><gtr:id>BE1D057F-EF70-4E6F-A2CD-3D2C2BE31443</gtr:id><gtr:impact>potential exploitation of our assay and parallel mouse experiments.</gtr:impact><gtr:outcomeId>58c1668e30e8b6.38406935-1</gtr:outcomeId><gtr:partnerContribution>potential exploitation of our assay and parallel mouse experiments.</gtr:partnerContribution><gtr:piContribution>potential exploitation of our assay and parallel mouse experiments.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TEVA Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:description>Teva</gtr:description><gtr:id>89C0CA2D-0BE5-4532-8A2C-8E03EAE31FF3</gtr:id><gtr:impact>potential exploitation of our assay and parallel mouse experiments.</gtr:impact><gtr:outcomeId>58c16664a8e700.71314753-1</gtr:outcomeId><gtr:partnerContribution>potential exploitation of our assay and parallel mouse experiments.</gtr:partnerContribution><gtr:piContribution>potential exploitation of our assay and parallel mouse experiments.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ESOT</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B9EFD599-FB95-4AF6-AEEB-6CA71436BE85</gtr:id><gtr:impact>presented at 'European Society for Organ Transplantation' conference</gtr:impact><gtr:outcomeId>58c1683750fe91.72488800</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Transplant Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E74F8EF-00D2-439A-89C0-C4A906C82980</gtr:id><gtr:impact>presented nationally and internationally at 'British Transplant Society' conference</gtr:impact><gtr:outcomeId>58c167efc1c201.40438180</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Industry Stakeholder Event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8F30116D-2C37-4A49-8A5B-A08553163F1E</gtr:id><gtr:impact>Industry delegates attended Medical Device Symposium relating to fMRI neurofeedback field</gtr:impact><gtr:outcomeId>58c1677eeb8c88.63484710</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>http://www.uc.pt/en/fmuc/ibili/MedicalDeviceSymposium/Agenda</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Life Sciences Research Network Wales</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Welsh Assembly</gtr:fundingOrg><gtr:id>48C7EF27-9DBC-4E77-A024-F059E606E2AA</gtr:id><gtr:outcomeId>56ddab8be18186.49010744</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Strategic Award</gtr:department><gtr:description>Wellcome ISSF</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A61329DA-8F35-475C-8F32-00C4DEAB8A82</gtr:id><gtr:outcomeId>58c16262af8a37.92721271</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Life Sciences Bridging Fund</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:id>9050521A-CCA7-4108-89EE-43400B3A9755</gtr:id><gtr:outcomeId>58c160beac76e7.02249765</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cardiff Partnership Fund</gtr:description><gtr:fundingOrg>Cardiff Partnership Fund</gtr:fundingOrg><gtr:id>976D1F6A-60AC-4719-BAE0-B511F6012B82</gtr:id><gtr:outcomeId>58c1608d617949.76728510</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Renishaw Ltd</gtr:description><gtr:fundingOrg>Renishaw plc</gtr:fundingOrg><gtr:id>90D94BAD-5922-4D7F-8C86-9346F71D82DD</gtr:id><gtr:outcomeId>58c1602a4dc151.86380424</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>84104</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dunhill Medical Research Trust</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>The Dunhill Medical Trust</gtr:fundingOrg><gtr:id>DF47C73C-3E39-45F0-A732-2C9BE859E6C4</gtr:id><gtr:outcomeId>58c15feb3d94f5.92973485</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>304780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Fellowship</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>564A4525-87A8-4545-A048-819ECC87CA3F</gtr:id><gtr:outcomeId>58c161a74c7e80.50400596</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>141000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CHDI Foundation</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>B2E4F327-4305-4593-90EC-1D19E3D8DF61</gtr:id><gtr:outcomeId>58c162226e3475.45593342</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EHDN Seed Fund</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>European Huntington's Disease Network (Euro-HD)</gtr:fundingOrg><gtr:id>3089E6E2-58DD-4A81-BC25-054B35280799</gtr:id><gtr:outcomeId>58c1613c964718.73429675</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Permipatch</gtr:description><gtr:grantRef>MC_PC_14108</gtr:grantRef><gtr:id>2121E373-A6BA-41A9-BE4C-65F1CFEA0FE3</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c166d45f4f75.33058344</gtr:outcomeId><gtr:protection>Patent application published</gtr:protection><gtr:title>Permipatch</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>dental pulp stem cells banked</gtr:description><gtr:id>F2430EE3-9CB0-477A-8CF0-174CDEB78615</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>58c168c2f2b382.06837618</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>dental pulp stem cells</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cell-based assay for somatic instability</gtr:description><gtr:id>C03025CE-13C0-460E-B308-0BE8E0F1D221</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>58c1688aa62c26.90859544</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell-based assay for somatic instability</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>89433750-6BCA-4CB8-8FC3-67DE7ABB8EA2</gtr:id><gtr:title>demonstrates pathogenicity through increased attachment in anpolymicrobial pulpal infection.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8a26c8233e4668c5aef610cccfcb4b7"><gtr:id>c8a26c8233e4668c5aef610cccfcb4b7</gtr:id><gtr:otherNames>Nishio Ayre W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5aa12c893eae35.86849247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1613616A-53CA-49F1-B8F4-709895AEB9CB</gtr:id><gtr:title>Liposomal Delivery of Demineralized Dentin Matrix for Dental Tissue Regeneration.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68b729034b6d4c58e62ea24c9fd8ba53"><gtr:id>68b729034b6d4c58e62ea24c9fd8ba53</gtr:id><gtr:otherNames>Melling GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5aa12c89761605.23174324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95E0CCF7-78B7-47FA-9994-6FD9AAF2BA05</gtr:id><gtr:title>DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>58c16499b41fa3.76431832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DDCF79A-F5C7-4B4F-9989-D0D60B4DF6BE</gtr:id><gtr:title>In vitro permeation and biological activity of punicalagin and zinc (II) across skin and mucous membranes prone to Herpes simplex virus infection.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c4a298f63b457b08d7fd48a4fa51af7"><gtr:id>7c4a298f63b457b08d7fd48a4fa51af7</gtr:id><gtr:otherNames>Houston DMJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0928-0987</gtr:issn><gtr:outcomeId>58c163afd400f3.18227182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E6AA252-1F85-4048-9D2E-37E74442BDA1</gtr:id><gtr:title>Analysing the bioactive makeup of demineralised dentine matrix on bone marrow mesenchymal stem cells for enhanced bone repair.</gtr:title><gtr:parentPublicationTitle>European cells &amp; materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ee5477231b2c188599f38f04977eb9"><gtr:id>88ee5477231b2c188599f38f04977eb9</gtr:id><gtr:otherNames>Avery SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-2262</gtr:issn><gtr:outcomeId>5aa12c89c54378.28692369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CCF6DBB-C6A3-42DA-B28C-B81587F00DD5</gtr:id><gtr:title>Real-time functional magnetic resonance imaging neurofeedback in motor neurorehabilitation.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22a6d7ab17cbb12da418576166613bb9"><gtr:id>22a6d7ab17cbb12da418576166613bb9</gtr:id><gtr:otherNames>Linden DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>58c162fd6f6a03.08682718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C840689D-220B-4CBD-B2CB-6461AD9AF111</gtr:id><gtr:title>Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study</gtr:title><gtr:parentPublicationTitle>The Lancet Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1e54c444e03a33c202183aaefe829d2"><gtr:id>f1e54c444e03a33c202183aaefe829d2</gtr:id><gtr:otherNames>Moss D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa11fb7ead9f1.89774970</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14108</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>